Interim report 2026
Filed with HKEX · Stock code 2171 · · 81 pages · English
Summary by 6ix AI
The report indicates that the company generated revenue primarily from its CAR T-cell product, zevorcabtagene autoleucel, and reported a net loss for the period. Additionally, the report outlines significant advancements in the company's product pipeline, including approvals and ongoing clinical trials for its therapies. The company also successfully raised funds through a placing to support its clinical development efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
CARsgen Therapeutics Holdings Ltd. on 6ix
Earlier from CARsgen Therapeutics
- CARsgen Therapeutics Announces 2026 Interim Results
- CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
- CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
- Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
- CARsgen Therapeutics Announces 2025 Annual Results
Later from CARsgen Therapeutics
- Voluntary announcement - first patient dose of CT1190B in china phase i registrational trial
- Resignation of non-executive director and non-compliance with rule 3.21 of the listing rules
- List of directors and their roles and functions
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - first patient dose of CT0596 in china phase i registrational trial
Follow CARsgen Therapeutics into a list and get an email when it puts out news.
Follow CARsgen Therapeutics